Compare PEB & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | TNDM |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2009 | 2013 |
| Metric | PEB | TNDM |
|---|---|---|
| Price | $12.29 | $20.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 17 |
| Target Price | $12.35 | ★ $24.06 |
| AVG Volume (30 Days) | ★ 2.1M | 1.2M |
| Earning Date | 02-25-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,464,126,000.00 | $1,007,001,000.00 |
| Revenue This Year | $2.11 | $8.59 |
| Revenue Next Year | N/A | $10.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.99 | ★ 17.87 |
| 52 Week Low | $7.42 | $9.98 |
| 52 Week High | $14.21 | $37.93 |
| Indicator | PEB | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 63.55 | 40.47 |
| Support Level | $12.01 | $20.21 |
| Resistance Level | $12.95 | $23.95 |
| Average True Range (ATR) | 0.42 | 1.11 |
| MACD | 0.04 | -0.39 |
| Stochastic Oscillator | 64.66 | 0.03 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.